Search results
Prostate Cancer: New Urine Test May Help Reduce Unnecessary Biopsies
Healthline· 3 days agoA prostate cancer biomarker test that utilizes 17 genetic markers has demonstrated a high degree of accuracy in screening for serious cancer. The test also significantly reduced ...
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional...
Morningstar· 2 days agoXTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the ...
Urine Test Detects High-Grade Prostate Cancer
Technology Networks· 7 days agoResearchers at the University of Michigan Health Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate...
What Happens to Your Body When You Eat Tomatoes Regularly
Eating Well via Yahoo News· 1 day agoSeveral studies have shown that eating tomatoes regularly, particularly cooked tomatoes, is...
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
Morningstar· 5 hours agoCandel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight ...
Have Male Urinary Tract Symptoms? An App May Offer Relief
WebMD· 1 day ago“We think flexibility in time and location for our patients is a high priority,” said Christian Gratzke, MD, the study’s lead investigator and urologic surgeon at University Hospital Freiburg ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoA solution for Urgency + Frequency, the new product advances women’s bladder health naturally, featuring science-backed Flowens® for overactive bladder (OAB). Bethlehem, PA, April 20, 2024— ...
Experts: Here Are 5 Ways to Lower Your Risk of Dementia
MediaFeed via AOL· 1 day agoAbout a third of Alzheimer’s cases are preventable, according to a spate of recently published...
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 2 days agoA phase III registrational study is expected to begin in 2025. For the acquisition, AstraZeneca will...
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation...
Digital Journal· 1 day agoThe primary objectives of the trial include determining the maximum tolerated dose and/or recommended Phase 2 dose and evaluating antitumor activity of tulmimetostat monotherapy. The safety ...
